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Background: Despite potential benefits, the practice of incorporating pharmacogenomics (PGx) results in
clinical decisions has yet to diffuse widely. In this study, we conducted a review of recent discussions on data
standards and interoperability with a focus on sharing PGx test results among health systems. Materials
& methods: We conducted a literature search for PGx clinical decision support systems between 1 January
2012 and 31 January 2020. Thirty-two out of 727 articles were included for the final review. Results: Nine of
the 32 articles mentioned data standards and only four of the 32 articles provided solutions for the lack of
interoperability. Discussions: Although PGx interoperability is essential for widespread implementation,
a lack of focus on standardized data creates a formidable challenge for health information exchange.
Conclusion: Standardization of PGx data is essential to improve health information exchange and the
sharing of PGx results between disparate systems. However, PGx data standards and interoperability are
often not addressed in the system-level implementation.
First draft submitted: 9 May 2020; Accepted for publication: 22 June 2020; Published online:
30 October 2020
Keywords: clinical decision support systems • health information exchanges • health information interoperability •

implementation science • pharmacogenomics study

Pharmacogenomics (PGx) is well established as an important factor for improving drug efficacy and reducing
adverse events [1,2]. Many studies have found PGx screenings to be cost-effective due to the decreasing cost of
tests [3–5]. Moreover, a combination of economic, humanistic and clinical considerations necessitates the use of
PGx as a tool to deliver optimal patient care. Identifying genetic dispositions is critical for predicting successful
or failed medication therapy. With the advent of precision medicine and big data in healthcare, it is momentous
to incorporate PGx for optimizing medication therapy outcomes [6–8]. Different governing bodies have established
guidelines for incorporating PGx results into clinical practice due to the pivotal role PGx plays on the treatment
regimen. The US FDA published biomarker and association tables to identify important drug-gene interactions
easily [9]. Moreover, the NIH has funded the Pharmacogenomics Research Network (PGRN), catalyzing the
formation of other resources such as PharmGKB for PGx knowledge base and PharmVar for allelic nomenclature.
Several international organizations, including Clinical Pharmacogenetics Implementation Consortium (CPIC),
Dutch Pharmacogenetics Working Group (DPWG) and the Canadian Pharmacogenomics Network for Drug
Safety (CPNDS), aim to give clinical dosing recommendations to prescribers.
The Centers for Medicare and Medicaid Services (CMS) established the PGx payment criteria for four genes
with specific drugs: CYP2C19, CYP2D6, and CYP2C9 and VKORC1 for clopidogrel, antidepressants and warfarin,
respectively. The commercial payers vary in their willingness to pay for tests, and the reimbursements are based
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on a case by case scenario. In 2012, current procedural terminology (CPT) codes for PGx were established
for easier documentation and billing [10]. Moreover, genetic counseling is a billable service for both physicians
and genetic counselors with an established CPT code [11]. As PGx testing becomes a more ubiquitous practice,
reimbursement practices must follow to provide comprehensive care to patients. Therefore, the congress passed the
Genetic Information Nondiscrimination Act (GINA) that prevents health insurance enrollment and employment
discrimination based on genetic disposition to reassure patient protection and encourage testing for susceptible
patients in 2008. State-specific GINA, such as CalGINA, further prevents discrimination in housing, education
and public accommodations [12].
Health Information Technology for Economic and Clinical Health Act (HITECH) of 2009 served as an
investment from the Office of the National Coordinator (ONC) to improve the use of technology within healthcare.
The program incentivized providers and health systems to adopt electronic health records (EHRs) to store patient
data to promote meaningful use [13]. Clinical decision support systems (CDSSs) are extensions of existing health
information technology designed to aid novice and expert clinicians in medical decision-making by using evidencebased recommendations or alerts [14]. CDSSs are often integrated into EHRs for most laboratory result values ready
for review at the point-of-care [15–17]. For PGx CDSSs, many studies report integrating PGx testing results into
EHRs [18–20]. The Implementing Genomics in Practice (IGNITE) network successfully integrated PGx CDSSs in
six different sites within the USA [18]. Each site had different ways of integrating CDSSs into the EHRs. Another
functional PGx CDSS implementation is from the Mayo Clinic’s RIGHT protocol. The CDSSs were integrated into
the EHR for providers. Also, patients were able to review results on their online patient portals [19]. The Electronic
Medical Records and Genomics (eMERGE) network supported developing algorithms for utilizing genotyping and
phenotyping data electronically for PGx candidate genes in several sites across the nation. However, no universal
standards exist yet for an external CDSS [21]. Many study sites, including Mayo Clinic, University of Chicago,
University of Florida, eMERGE and the IGNITE Networks sites, continue to utilize and implement PGx CDSSs
within the health systems. Globally, PGx CDSSs are continuously operating in various preemptive and reactive
testing settings in various countries, including the European Union. Although multiple PGx CDSS implementations
exist, studies describing a successfully incorporated PGx into clinical practice focus mainly on developing clinical
result reporting, CDSS alerts and provider education [22,23]. Although these PGx initiatives by multiple sites have
shown the feasibility of implementing PGx into clinical practice, barriers exist in the widespread PGx utilization –
interoperability. Given the stable nature of the germline variant data and the clinical utility of the PGx information,
the highest level of interoperability is critical to facilitate a secure, seamless and timely communication of the PGx
results both within and between healthcare organizations, entities and individuals.
The HITECH act encouraged the use of technology to improve patient care by integrating CDSSs into EHRs for
wider adoption. Nevertheless, the interoperability becomes a concern due to the inability of each unique system to
communicate with each other [24,25]. In response to this problem, the ONC added a Health Information Exchange
(HIE) initiative to address interoperability between and within systems. However, such initiatives are currently still
limited. The Veterans Affairs is set to launch an interoperable system for veterans who visit a non-veterans affairs
care provider. The Veterans Health Information Exchange will thus allow for secure access to patient health lab
results, notes and health information to community providers [26]. Other impending HIE programs are slower to
progress. One of those reasons is the lack of a broader vision to incorporate data standardization [27,28].
Data standardization is particularly important in healthcare since EHR vendors represent data differently.
Electronically, systems are unable to recognize the difference in data formatting, which results in the inability
to exchange information. Thus, exchanging data without the use of standards risks the misinterpretation of the
data. The exchange of PGx results is especially important since the results are reusable and constant throughout a
patient’s lifetime. If a patient wants to change health plans or primary care provider, the new healthcare provider
should have access to previously tested PGx results. The lack of data standardization prevents results from being
shared electronically between different health systems. To facilitate the HIE process, CPIC term standardization
efforts have lead to the development of LOINC and SNOMED terms. Even with the data standards in genomics,
implementation of PGx-specific standards are not prevalent. Many studies expressed the need for fully developed
PGx data standardization [29–31]. Therefore, data standards in laboratory processes, reporting of the results, and
reimbursement processes are crucial for achieving PGx data interoperability.
Clinical workflow recommendations have been incorporated into CDSS prototypes due to the emerging relevance
and importance of PGx tests. PGx CDSSs provide a knowledge source and education for clinicians, create clinical
recommendations and ensure dosing adjustments based on PGx test results and alert notifications [22,32–34].
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However, a gap exists in the PGx CDSS literature. Many papers and reviews discuss PGx integration solely into
EHRs without CDSSs or discuss CDSSs without considering data standards. Articles mention the need for data
standardization in PGx; however, do not go in-depth about possible solutions for the future of health information
exchange [35]. Our study aims to review PGx CDSSs piloted or prototyped and seeks to determine if interoperability
between different EHRs was discussed or addressed. The Preferred Reporting Items for Systematic Reviews and
Meta-Analysis (PRISMA) guidelines were utilized to report this review [36].
Materials & methods
The literature search focused on articles describing PGx implementation with CDSSs. The inclusion criteria for the
search for articles had two main focus: articles related to PGx system implementation and articles related to PGxrelated protocol or module implementations in a decision support system or EHRs. Exclusion criteria were PGx
implementation into health systems or utilizing PGx reports for clinical decisions without a CDSS, review articles,
abstracts, conference posters, brief reports, case reports, correction communications, rapid communications, posters
or abstracts, articles not in English and research describing neither PGx nor CDSS. The risk of bias was not assessed;
however, similar study-locations were grouped together.
Literature search

A literature search was conducted in January 2020 for articles published between 1 January 2012 and 31 January
2020 using five databases: PubMed, Web of Science, Google Scholar, Scopus and Embase. The keywords used in
the PubMed search query included (‘clinical decision support’ [MeSH Terms] or ‘decision support’ or ‘decision
making’) and (‘pharmacogenetics’ [MeSH Terms] or ‘pharmacogenetic’ or ‘pharmacogenomic’). A PGx CDSS for
even a single gene was included and screened for eligibility. Two reviewers independently screened titles, keywords
and abstracts of articles for relevance and duplications. Both reviewers analyzed full-text articles and discussed the
disagreements for consensus. Figure 1 summarizes the article selection process.
Data collection

Data standards for CDSSs were assessed in the full-text articles that met the inclusion criteria. Data items abstracted
included ‘system or project name’, ‘study location’, ‘data standard for PGx CDSS’, ‘interoperability summary’ and
’system-related interoperability features in the PGx CDSS. The PGx system name was identified throughout the
article as the project name. If there was none mentioned, it was listed as ‘no name’. The study location was the
main geographic location of where the CDSS study was conducted [23]. Data standards for PGx CDSS were
defined as systems or rules adhered to standardize reporting of PGx data, which includes Health Level Seven
(HL7) as it relates to interoperability. The standardization of laboratory reports, variants reporting or clinical
recommendations was not included in the definition for the purposes of this review. The interoperability summary
was abstracted from direct quotes addressing interoperability in each article. Finally, interoperability features and
designs were summarized to understand the extent of the health information exchange implemented into the
CDSSs. The findings were summarized in two tables with descriptive narratives.
Results
A cumulative of 727 articles were identified from all five databases. Of these, 650 articles were excluded by title and
abstract screening for duplication or describing a CDSS not pertaining to PGx or PGx-related medication data.
Seventy-seven full-text articles were reviewed. Fort-five articles were excluded due to three reasons: 17 articles were
not full-text articles and were conference abstracts, 19 studies did not describe a PGx CDSS and the remaining
nine articles did not integrate actual PGx data into the CDSS. Finally, 32 articles were evaluated in this review.
Data standards

Nine of the 32 studies mentioned data standards, such as HL7, and all but two utilized HL7 to report results into
EHR or external systems, as detailed in Table 1 [29,31,37–43]. The remaining 23 articles mentioned standardized
guidelines in regard to clinical recommendations, like CPIC and DPWG, but were unrelated to standardizing
reporting of results [19,20,30,34,44–61]. In particular, Bousman et al. described four different PGx CDSSs from different
companies to determine the consistency and accuracy of results. Overall, 58% of medication recommendations
from the four PGx CDSSs reported similar results. Forty-two percent differed in their representation or clinical
recommendations of results. Additionally, among patients with actionable genes identified by CDSS flags, 19% of
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Table 1. Results of thirty-two articles describing pharmacogenomics clinical decision support systems, data standards and
interoperability.
System or project name

Study location

Data standards for PGx CDSS

Ref.

1. TPMT CDS testing

Mayo Clinic, Rochester, MN, USA

HL7

[43]

2. PGTIC

National Institutes of Health Clinical
Center, Bethesda, MD, USA

HL7, Arden Syntax

[39]

3. PGTIC

National Institutes of Health Clinical
Center, Bethesda, MD, USA

HL7, Arden Syntax

[40]

4. GACS

Elimu Informatics, Richmond, CA, USA

HL7 FHIR

[41]

5. SHARPc-2B

Arizona State University, Scottsdale, AZ,
USA

HL7, UML

[29]

6. FARMAPRICE

Aviano Hospital, Aviano Italy

HL7, IHE, DICOM, XDS

[42]

7. The U-PGx project

Various institutions across
seven different countries: Austria,
Spain, Greece, Great Britain, Italy,
Slovenia and The Netherlands

HL7 FHIR, HTTPS

[37]

8. PREDICT (2012)

Vanderbilt University School of
Medicine, Nashville, TN, USA

HL7
Peterson et al. mentioned that they will
integrate HL7 in the future when
standardization is better developed;
Pulley et al. did not mention standards

[48]

9. PREDICT (2013)

Vanderbilt University School of
Medicine, Nashville, TN, USA

Peterson et al. mentioned that they will
integrate HL7 in the future when
standardization is better developed;
Pulley et al. did not mention standards

[31]

10. GPS portal (2012)

University of Chicago, Chicago, IL, USA

Danahey et al. mentioned HL7 SMART
on FHIR but did not integrate into
system; all others did not mention
standards

[53]

11. GPS (2014)

University of Chicago, Chicago, IL, USA

Danahey et al. mentioned HL7 SMART
on FHIR but did not integrate into
system; all others did not mention
standards

[59]

12. GPS (2014)

University of Chicago, Chicago, IL, USA

Danahey et al. mentioned HL7 SMART
on FHIR but did not integrate into
system; all others did not mention
standards

[59]

13. GPS (2017)

University of Chicago, Chicago, IL, USA

Danahey et al. mentioned HL7 SMART
on FHIR but did not integrate into
system; all others did not mention
standards

[34,38]

14. No name

Emory University School of Medicine,
Atlanta, GA, USA

Discussed the need for data
standardization but did not mention
standards

[30]

15. CPS

Boston Children’s Hospital (BCH),
Boston, MA, USA

None

[63]

16. MSC (2014)

University of Vienna, Vienna, Austria
University of Pittsburgh, Pittsburgh, PA,
USA

None

[44]

17. MSC (2015)

University of Pittsburgh, Pittsburgh, PA,
USA

R
18. UW-PowerChart
prototype

University of Washington, Seattle, WA,
USA

[45]
None

[46]
[19]

19. RIGHT

Mayo Clinic, Rochester, MN, USA

None

20. Right Drug, Right, Dose, Right Time

Mayo Clinic, Rochester, MN, USA

None

[47]

21. PMP

Cleveland Clinic Health System,
Cleveland, OH, USA

None

[62]

22. PMP

University of Florida, Gainesville, FL,
USA

None

[50]

CDSS: Clinical decision support system; CPS: Clinical pharmacogenomic service; DICOM: Digital Imaging and Communications in Medicine; FHIR: Fast healthcare interoperability resources;
GACS: Genomic Archiving and Communication System; GPS: Genomic prescribing system; HL7: Health level seven; HTTPS: Hypertext transfer protocol secure; IHE: Integrating the healthcare enterprise; MSC: Medicine Safety Code; PGTIC: Pharmacogenetics Testing Implementation Committee; PGx: Pharmacogenomic; PMP: Personalized Medication Program; PREDICT:
Pharmacogenomic Resource for Enhanced Decisions in Care and Treatment; SMART: Substitutable Medical Applications and Reusable Technologies; UML: Unified Modeling Language;
U-PGx: Ubiquitous Pharmacogenomic; XDS: Cross-enterprise document sharing.
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Table 1. Results of thirty-two articles describing pharmacogenomics clinical decision support systems, data standards and
interoperability (cont.).
System or project name

Study location

Data standards for PGx CDSS

Ref.

23. PG4KDS (2014)

St. Jude Children Research Hospital,
Memphis, TN, USA

None

[51]

24. PG4KDS (2014)

St. Jude Children Research Hospital,
Memphis, TN, USA

None

[52]

25. CLIPMERGE PGx

Icahn School of Medicine at Mount
Sinai, New York, USA

None

[21]

26. TreatGx

University of British Columbia,
Vancouver, BC, Canada

None

[54]

27. CDST Youscript (2017)

White County Medical Center, Searcy,
AR, USA

None

[55]

28. CDST Youscript (2018)

Magellan Health, Salt Lake City, UT, USA None

[56]

29. PGx CDS

University of Washington, Seattle, WA,
USA

None

[57]

30. eMERGE-PGx project

Multiple sites within the USA

None

[20]

31. CYP-GUIDES

Hartford Hospital, Hartford, CT, USA

None

[58]

32. The Implementation of
Pharmacogenetics into Primary care
Project (IP3 study)

Leiden University Medical Center, The
vicinity of Leiden, The Netherlands

None

[60]

CDSS: Clinical decision support system; CPS: Clinical pharmacogenomic service; DICOM: Digital Imaging and Communications in Medicine; FHIR: Fast healthcare interoperability resources;
GACS: Genomic Archiving and Communication System; GPS: Genomic prescribing system; HL7: Health level seven; HTTPS: Hypertext transfer protocol secure; IHE: Integrating the healthcare enterprise; MSC: Medicine Safety Code; PGTIC: Pharmacogenetics Testing Implementation Committee; PGx: Pharmacogenomic; PMP: Personalized Medication Program; PREDICT:
Pharmacogenomic Resource for Enhanced Decisions in Care and Treatment; SMART: Substitutable Medical Applications and Reusable Technologies; UML: Unified Modeling Language;
U-PGx: Ubiquitous Pharmacogenomic; XDS: Cross-enterprise document sharing.

Table 2. Interoperability features and designs used in pharmacogenomics clinical decision support systems.
System or project
name

Interoperability summary

System-related interoperability features in the PGX CDSS

Ref.

U-PGx

The study aimed to address interoperability by ensuring sharing
PGx results within and between different healthcare settings in
different European countries. They recognized improving
interoperability through GIMS would successfully implement
preemptive PGx testing.

GIMS includes:
– Secure data transfer of PGx results and dosing recommendations
(HL7, .csv, HTTPS, FHIR and RESTful) into EHR
– PGx report in PDF or ODF into patient’s paper based or digital file
– Medication Safety-Code card for facilities without EHR

[37]

GACS

The authors stated that genetic sequencing data and EHR data
standards have independently advanced creating a bigger issue of
interoperability. In order to address this gap GACS was utilized to
store data and the authors proposed using CDS Hooks, PGx CDSS
that can be rendered.

External data storage in GACS and results expressed in FHIR and
CDS hooks
CDS hooks notify the external GACS to receive or generate PGx
data and communicate back to EHR.

[41]

SHARPc-2B

The authors published a guideline for PGx in order to combine
standards to create a structured document that can be shared with
the machine-readability. The guideline aims to be a starting point
for PGx CDS for evidence-based care delivery.

PGx guideline using:
– UML diagrams
– HL7 vMR, LS DAM and HL7 RIM
– RxNorm, NDF-RT, SNOMED CT and LOINC

[29]

FARMAPRICE

The study recognized that even in a country with universal
healthcare, the healthcare technology infrastructure may be still
fragmented as evidenced by different EHRs throughout the Italy.
The lack of a single EHR was described as a barrier to
interoperability and sharing healthcare data.

Open source solutions include:
– Protected Health Information technology
– Independent from the underlying operating system
– Reports results on the latest open standards (HL7, IHE, DICOM
and XDS)

[42]

CDS: Clinical decision support; CDSS: Clinical decision support systems; csv: Comma-separated values; DICOM: Digital imaging and communications in medicine; EHR: Electronic Health
Record; FHIR: Fast healthcare interoperability resources; GACS: Genomic archiving and communication system; GIMS: Genetic information management suite; HL7: Health level seven;
HTTPS: Hypertext transfer protocol secure; IHE: Integrating the healthcare enterprise; LOINC: Logical observation identifiers names and codes; LS DAM: Life sciences domain analysis model;
NDF-RT: National drug file – reference terminology; ODF: Open document format; PDF: Portable document format; RIM: Reference information model; RESTful: Representation State Transfer;
SNOMED CT: Systemized Nomenclature of Medicine – clinical terms; UML: Unified modeling language; vMR: Virtual medical record; XDS: Cross-enterprise document sharing.

those flags reported different clinical drug dosing recommendations for the same PGx variant [30]. Although many
studies did not discretely state the reporting PGx data standards used, most studies recognized the lack of data
standardization leading to the creation of individual protocols and standards [19,20,31,47,49–51,62].
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727 articles identified
650 articles excluded
– Did not describe:
PGx CDSS or
PGx medication data
– Duplicate articles

77 full text articles
assessed
45 full text articles excluded
Not primary article: 17
Not describing fully developed
PGx CDSS: 19
No actual PGx data integration
into CDSS: 9

32 articles included

PGx CDSS data
standards
Nine articles mentioning
standards

Interoperability
Four articles address
interoperability

Figure 1. Literature search and process of article selection.
CDSS: Clinical decision support system; PGx: Pharmacogenomics.

Interoperability

Out of the 32 articles evaluated, eight articles mentioned interoperability to a varying extent. Four briefly mentioned
the need for data standardization and interoperability. These four studies did not discuss data standards in detail
but considered it as a challenge while creating PGx CDSSs. The remaining four studies addressed interoperability
by creating prototypes and implementing features into the system as solutions. The details of data standards used
in response to the lack of data standardization in these studies are shown in Table 2.
Dolin et al. and Blagec et al. presented a similar approach to health information exchange by using an external
genomic system as a source of CDSS [37,41]. The U-PGx project was created to implement PGx CDSSs in seven
different European countries by using a web-based knowledge source called Genetic Information Management
Suite (GIMS) [37]. GIMS translates genomic data into clinically actionable recommendations, stores results and
serves as a knowledge base. For result reporting, GIMS creates reports compatible with different reporting standards
(HL7, Fast Healthcare Interoperability Resources [FHIR] and Hypertext Transfer Protocol Secure [HTTPS]) and
sends results to EHRs. For sites that lack an EHR, a medication safety code was created in order to review the
PGx results on a web site. Furthermore, U-PGx aimed to keep records into patient’s medical files using a portable
document for paper-based reports or open document format for electronic files. The combination of using GIMS
and medication safety code enabled the sharing of results not only within and between systems but also across
countries. As of June 2017, GIMS was fully functional and being continuously utilized in three different countries.
Similar to the U-PGx project, Genomic Archiving and Communication System (GACS) serves as an external
functional prototype for PGx CDSS [41]. GACS houses complete DNA sequencing data and can retrieve genetic
information and feed into the EHR through clinical decision support (CDS) Hooks. CDS Hooks are application
programming interfaces that use the ‘hook’ method for invoking CDS rules to enable communication between an
external decision system and the EHR. A PGx CDSS was modeled alongside GACS to provide clinical recommen-
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dations based on the genetic information from GACS by using FHIR. In January 2018, this demonstration was
completed using GACS and the PGx CDSS for TPMT and azathioprine.
The FARMAPRICE study created a prototype that used an open-source Protected Health Information Technology that operates independently as a web-based platform and has the potential to be integrated into EHRs [42].
FARMAPRICE CDSS was created in response to the lack of a standardized EHR platform to share results between
health systems across Italy. Thus, the application supports reporting results in the latest standards (HL7, Integrating
the Healthcare Enterprise [IHE] and Digital Imaging and Communications in Medicine [DICOM]), ensuring the
interchange of PGx results between different operating systems for future use. The prototype is currently under
further research and developmental use at Aviano Hospital in Italy.
In the SHARPc-2B project, the authors created a PGx guideline to combine standards (Unified Modeling
Language [UML], HL7 vMR and terminology) and a shareable PGx CDSS using the ONC supported Health
eDecisions (HeD) interchange format [29]. The PGx CDSS guideline by HeD was created using UML, SNOMED
CT, RxNorm and LOINC. Using HeD, the authors were able to create a model for HLA-B and abacavir that could
be utilized in health systems desiring to integrate PGx into clinical practice with a standardized guideline.
Discussion
PGx research has broadened over time to include studying PGx tests as a clinical component of patient care within
the context of CDSS integrated with EHRs. The studies that have been published within the last 8 years have
mainly focused on CDSS alerts, developments or features [23,33]. Although many CDSS have been created to offer
CDS to providers in patients with actionable genotypes, the discussion of data standards and interoperability has
been limited [64]. Some of the data standards mentioned within the articles included SNOMED CT, LOINC, HL7,
DICOM and IHE. However, most of the discussions were only limited to mentioning the use of standardized
terminology. On the contrary, genomics data have been standardized based on the need to compare thousands
of different datasets [65]. As a result, genomics data have been standardized to be shared, managed and analyzed.
An example of genomic data standards includes the HL7 V3 Clinical Genomics Standard Specifications, which
combines raw genomic data to a patient phenotype [66]. Additionally, the Genomic Knowledge Standards Work
Stream (GKSWS) group works to standardize genomic data to improve compatibility with healthcare standards
(HL7 and FHIR). Similarly, PGx data must be standardized as genomics data for smooth information exchange
between health systems. Yet, PGx standardization has been slow to progress through continuous development.
Only CPIC discussed and published standardized data to identify PGx terms for allele functions and associated
phenotypes. Moreover, the improvement in standardization was furthered as SNOMED CT incorporated the
standardized terms created by CPIC [67,68]. The final study we reviewed was a guideline to model PGx CDSS into
an ONC initiated HeD schema. In creating the guideline, standard terminologies were used such as RxNorm,
LOINC and SNOMED CT. However, the authors noted that codes for adverse drug reactions of abacavir and
genotype test results were unavailable. As a result, the authors concluded that harmonizing standards for PGx was
underdeveloped.
Data standardization is necessary for creating interoperable systems for PGx. Over the last 11 years, the government has been investing in converting healthcare into a more efficient and cost-saving system with the use
of technology. Investments from HITECH and HIE from the US government has funneled more than 2 billion
dollars into the health care system [13]. Without widespread data standardization adoption, this investment would
be unproductive. Our literature search has shown that among the papers addressing PGx integration into clinical
care through CDSSs, only four had taken interoperability into account. Although each study addressed interoperability with different aspects and system features, none of these studies reported data exchange mechanism between
different systems. Only the U-Pgx project addressed various data exchange scenarios, including non-electronic data
sharing. However, the U-Pgx project did not adequately address utilizing a standardized dataset for PGx.
Data standardization approval requires lengthy reviews and testing periods. Through an accredited collaborative
process involving various stakeholders and users, Standards Development Organizations (SDOs) define, maintain
and update standards. Prominent SDOs in the US healthcare sector are HL7, FHIR, Accredited Standards
Committee X12 (ASC X12), Integrating the Healthcare Enterprise (IHE) and International Organization for
Standardization (ISO). Usually, based on business needs the SDO decides to develop a standard. This development
process enters rounds of voting, feedback, piloting the standard and making appropriate changes taking anywhere
from 2 to 3 years [69]. Studies indicated the importance of standardized terms required for electronic transfer, which
has been insufficiently expressed through contemporary methods [70]. Specifically for PGx data standardization,
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CPIC standardized terms have been supported as LOINC identifiers, SNOMED codes and tested by the CAP
proficiency testing programs. Standardization in the genetic testing platform, alleles/variants included in the testing,
reporting of the PGxs results, genotype to phenotype translation is still under development [71]. Moreover, FHIR
strategies such as Substitutable Medical Applications and Reusable Technologies (SMART) would be adaptive
technologies to support the flexibility of our knowledge evolution and informatics needs in the PGx realm.
Therefore, the next phase should be to standardize the format of the document architecture and secure transmission
of the data [72]. Also, users and SDOs should continue developing PGx data standards by collaborating with expert
opinion leaders.
Standardizing PGx test results data plays a significant role in interoperability. Additionally, data standards allow
the uniformity of data that can be both machine- and human-readable and used worldwide. For example, healthcare
officials are using standardized data to monitor current COVID-19 pandemic cases effectively to inform the public
about the gravity of the situation. Thus, data standards affect not only healthcare providers but also average people.
Few data standards to consider for public health information exchange include Clinical Document Architecture
(CDA) for the structure of clinical documents, HL7 for exchanging messages, FHIR for data transfer security. In
the future, if PGx data can be standardized, sharing the genomic and the medication data have the potential to
improve healthcare even further.
PGx results are clinically actionable throughout a patient’s lifetime. With PGx data standardization, patients
will be able to utilize their results anywhere they are treated. As mentioned in multiple studies, usability is an
important aspect of a stand-alone patient managed genomics system. Therefore, graphical user interfaces based
on user-centered design have the potential to engage both the providers and the patients [73,74]. An intuitive
interface for managing PGx test results can reduce the cognitive burden on providers and patients as well as simplify
the complexity in managing health information [75]. A patient managed genomics system may have usability features
such as simple navigation, cognitive design, viewing controls, secure sharing options, and embedded analytics for
empowering patients [38,42,76,77 ].
Creating a PGx CDSS, which is shareable within and between different operating EHRs and other systems, will
increase PGx data accessibility and utilization. As a result, PGx and medication information can be shared with
different healthcare providers. For example, pharmacists in the community pharmacies may use this information to
identify drug–gene interactions and recommend alternative therapies in collaboration with physicians. Moreover,
clinicians can use patients PGx information to optimize medication therapy, reduce adverse drug events and improve
medication adherence.
Future perspective
To summarize, our literature search suggests that PGx interoperability is a complex phenomenon mired by numerous
challenges related to a well-recognized need for PGx data standardization. The crucial gap missing in the literature
was the need for specific and workable features of proposed interoperable PGx CDSSs. In particular, current
discussions about interoperability within PGx CDSS are insufficient. Most studies discuss the need for data
standardizations but do not discuss which standards were used or referenced. We recommend that future PGx
CDSS implementation research discuss the importance of data standards, including standardized PGx terminology,
health information exchange and interoperability.
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Executive summary
• The lack of pharmacogenomics (PGx) data standards is a barrier to interoperability and widespread sustainable
utilization of PGx data.
• Healthcare data standards and interoperability in PGx clinical decision support systems (CDSS) have not been
properly addressed in the literature.
• A scoping literature review was done for articles related to PGx system implementation with a decision support
system in electronic health records to explore the depth of discussion on data standards in PGx.
• Of the 32 articles that fit the inclusion criteria, only four discussed details about the lack of interoperability and
system designs to overcome the lack of data standards.
• Current discussions about PGx data standardization are insufficient in the literature.
• Without further development into PGx data standards, patients and providers will not be able to utilize PGx
results efficiently.
• A patient managed pharmacogenomics system sharing PGx data with clinicians and family members may
ultimately empower patients to manage their own medication information.
• As more research into data standards progress, a shareable PGx platform could increase PGx utilization to
promote precision medicine.
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